CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending

Biotech R&D: CRISPR vs. Supernus - A Decade of Investment

__timestampCRISPR Therapeutics AGSupernus Pharmaceuticals, Inc.
Wednesday, January 1, 2014151300019586000
Thursday, January 1, 20151257300029135000
Friday, January 1, 20164223800042791000
Sunday, January 1, 20176980000049577000
Monday, January 1, 201811377300089209000
Tuesday, January 1, 201917936200069099000
Wednesday, January 1, 202026694600075961000
Friday, January 1, 202143863300090467000
Saturday, January 1, 202246164500074552000
Sunday, January 1, 202338733200091593000
Monday, January 1, 2024320653000
Loading chart...

Infusing magic into the data realm

Strategic Focus on R&D Spending: A Tale of Two Biotech Companies

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, CRISPR Therapeutics AG and Supernus Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, CRISPR Therapeutics AG increased its R&D spending by an impressive 25,500%, peaking in 2022 with a 30% higher investment than in 2020. This surge underscores their aggressive pursuit of cutting-edge gene-editing technologies. In contrast, Supernus Pharmaceuticals, Inc. maintained a more stable R&D budget, with a modest 367% increase over the same period. Their spending peaked in 2023, reflecting a strategic focus on steady growth and sustained innovation. This divergence highlights the varied approaches companies take in navigating the dynamic biotech landscape, each aiming to secure a competitive edge through strategic R&D investments.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025